Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how 91黑料 successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Digital solutions for an evolving COVID-19 environment
One of the top five pharmaceutical companies in the world selected 91黑料 to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.
Optimising biosimilar development
91黑料’s proactivity in risk mitigation, commitment to the study, project planning and communication contributed significantly to the ultimate success of the study.
CRF design for a cell-therapy, immuno-oncology study
91黑料 developed flexible, cost-effective CRF designs for a cell therapy immuno-oncology study, harmonising RECIST and iRECIST criteria while addressing re-treatment requirements and supporting sponsors in meeting study timelines.
Optimised adaptive trial design for oncology biotech
91黑料 assisted a US-based oncology biotech in overcoming timeline, data uncertainty, budget constraints, and pressure for publishable results by offering a cost-effective phase 3 trial design with interim analysis, enabling early efficacy and regulatory approval with minimal upfront investment.
Externalised Development Solutions
A newly formed company needed expertise to support asset due diligence and strategic development planning to build their portfolio. 91黑料 was asked to verify the company’s own due diligence assessments and requested 91黑料’s experience in designing and executing a more efficient clinical development programme.
Patient support services
A sponsor needed to recruit nearly 500 patients for a pivotal study in an ultra rare disease. The study's demanding protocol posed significant difficulties for patients. 91黑料 was able to revise the protocol, reducing patient burden, and implemented a global recruitment strategy and additional support that allowed recruitment to be completed ahead of schedule, saving the sponsor an estimated $700,000.
Comprehensive standalone DMC services
91黑料 provided a comprehensive DMC solution for a phase 2 NASH trial, overcoming challenges like coordinating data across multiple vendors and adjusting to rapid enrollment.
.jpg?crop=yes&w=1984&h=1043&a=0,141&itok=jQiJdko6 "Researcher using tablet for assessments"){kind=icon}
Quantitative risk assessments to meet regulatory submission requirements
91黑料 provided a tailored quantitative risk assessment solution to help a sponsor anonymize clinical study data and documents for regulatory submission and private data-sharing.
Improved adherence in a high-risk immunology study for a small biotech
A small US based biotechnology company sought 91黑料’s assistance for a high-risk immunology study with heavy investment and limited resources. The study was a phase 3 Lupus SLE study with a complex protocol governing 90 sites.
Due diligence for portfolio investments
For this client, 91黑料 has performed technical evaluations of more than sixty assets across a range of therapeutic areas and modalities, including assessing the development risks and probability of achieving registration and commercial success.
Prioritising high-quality expedited COVID-19 vaccines
Small biotech companies were key to pushing forward their research on mRNA and associated technologies and adapting candidate vaccines to combat COVID-19. 91黑料 was ideally placed to partner with these sponsors during the COVID-19 global pandemic.
Comprehensive due diligence
91黑料 was approached by a customer seeking our expertise in conducting drug asset evaluation consulting services. The client looked to evaluate pharmaceuticals suitable for in-licensing or co-development, placing particular emphasis on autoimmune diseases.
Let's collaborate
Discover how 91黑料's expertise transforms clinical trials.